2. Does the surgeon fatigue test change or is it variable in time? As one surgeon does this over and over, answers may become rote, rendering data inaccurate. 3. Variant histologies may effect surgical technique/difficulty, would consider just using pure urothelial carcinoma (or UC with only minimal variant histology). 4. How will you investigate time differences between diversion types and any ensuing effects on outcomes? (i.e. intracoporeal ONB takes longer than IC, both of which will take longer than open diversions). 5. How will you account for bias in fitness tracking as patients may alter their activity, knowing they are only tracked for a period of time. Could consider making this a constant (if feasible)? 6. Recommend statistics review to evaluate need for any power calculations or additional analyses that may prove useful for your comparisons.
REVIEWER
Abolfazl Hosseini Karolinska university hospital Stockholm, Sweden REVIEW RETURNED 10-Dec-2017
GENERAL COMMENTS
Very well designed study. Some comments which should be considered: 1. Early recurrence within 2 first years after cystectomy should also be mentioned as one of oncological outcomes 2. Surgeons undertaking iRARC need to have completed more than 30 cases (RARC with totally intracorporeal urinary diversion, it should be emphasised) 3. Please describe exclusion criteria for orthotropic neobladder as well 4. For more detailed description of "duration os surgery" as an intraoperative element, the operation time has be divided in cystectomy, LND and urinary diversion.
REVIEWER

Peter Herbison University of Otago, New Zealand
REVIEW RETURNED
18-Jan-2018
GENERAL COMMENTS
It has been shown many times that the most important methodological item to prevent bias in a randomised controlled trial is to hide the treatment allocation until participants have been entered into the trial. Using sealedenvelope.com will do this, but I think it deserves an explicit mention, especially in the abstract.
There is little about what will happen with missing data. I realise that the authors state that a detailed analysis plan will be written later, but it would be good to have some idea. In the protocol it says that participants can withdraw at any time without prejudicing their treatment. But it is not until you get to the information sheet that you find out what will happen to those peoples' data. It is also possible that participants will be withdrawn for other reasons than their desire to leave the study. What will happen to the data, and future data collection, for these individuals.
While there is no details to the analysis I have some comments about the brief outline that is given. The primary outcome if days alive and out of hospital in the first 90 days after treatment. Now you would hope that a large proportion would have the maximum possible, after accounting for the immediate post operation hospitalisation. Thus the outcome will be left skewed (right skewed is more normal) and will have many people on numbers near 90. I am not convinced that a log transform will make this variable suitable for a t-test. Even if 91-this outcome its used to make it right skewed, there is likely to be some issues with its distribution. I think some simulations of possible outcomes will have to be done to work out what is the best way to analyse this outcome.
In the analysis plan it will be good to discuss what will be done with the minimisation variables. It is normal to adjust for these, maybe as a secondary analysis.
It is possible in this study that there will be "hidden" clusters, for example by surgeon, or surgical team. It may be that there is only one surgical team per site, so adjusting for site should help with this, but if it is possible to have more than one surgeon/team per site then this should be allowed for in the analysis.
REVIEWER
Sameer Parpia
McMaster University, Canada REVIEW RETURNED 25-Jan-2018
GENERAL COMMENTS
The authors present a protocol for an RCT comparing two surgical techniques in patients with bladder cancer. The methods and statistics are presented adequately however, some issues need to be addressed:
1. The internal review component suggests that collection of secondary outcomes will be reviewed, but also sample size will be re-estimated if need be. Sample size re-estimation is based on the primary outcome -do the authors plan to look at primary outcome data? Will this be done in a blinded fashion?
2. Several secondary endpoints have been specified, however, no adjustment for multiple testing has been proposed. Please clarify.
3. How will missing data be handled?
4. Given unblended nature of the trial, are the authors concerned about investigator bias e.g. investigators may delay hospital discharge for particular patients
REVIEWER
Richard Jackson University of Liverpool
REVIEW RETURNED
26-Jan-2018
GENERAL COMMENTS
The authors present the protocol for a two are randomised trial comparing robot assisted radical cystectomy agains open radical cystectomy.
Whilst this is generally a well written manuscript with a clear description of the trial to be carried out, there are a few statistical queries which could do with further clarification and I have detailed these below:
Internal Answer: We thank the reviewer for this comment.
1-Is there a more objective measure of surgeon fatigue than the SurgTLX? when the surgeons will complete it, after surgery? In this case it may be subject to recall bias.
Answer: The SURG-TLX is a validated multidimensional, surgery-specific workload measure and has been employed in similar studies. We will deploy it immediately after RC (hopefully minimising recall bias) and to both arms (balancing risks from any bias in undertaking the tool). The SURG-TLX has been validated in minimal-access surgery; the six dimensions measured include mental demands, physical demands, temporal demands, task complexity, situational stress, and distractions.
2-Why didn't the authors choose BCI or CARE questionnaires? Do they consider the use of diversion-specific questionnaires?
Answer: We thank the reviewer for this comment. We considered the choice of questionnaires carefully, with the primary aim of our study to measure recover from RC. As such, we considered WHODAS 2 and QLQ-BLM30/C30 to be vital. Our key secondary aim was a cost effectiveness analysis and so EQ-5D-5L was also vital. Whilst additional questionnaires would be interesting, we were concerned about generating too many questionnaires for our participants, especially as they are also undertaking recovery exercises. The CARE questionnaire is an excellent measure of the patientclinician relationship, but we were restricted to keeping the number of questionnaires to a minimum.
Of relevance, patient feedback has indicated that questionnaire fatigue is likely, and we had to reduce the number and use short versions where available. For bladder cancer specific questionnaires, we considered five instruments validated for use in these patients. We decided that the BLM30 more suitable as it is widely used in MIBC, and the BCI lacks modularity. Additionally, the BLM-30 is paired with the C30 which assesses quality of life specific to cancer. Whilst diversion specific questionnaire would be interesting, we will have too low power to deliver meaningful data and larger cohorts are available.
3-What will be the randomization criteria to keep both groups balanced? factors like type of diversion and neoadjuvant chemotherapy may affect outcomes.
4-I assume patient groups will be balanced based on the cT stage. However, many patients upstage or downstage after RC and therefore oncological outcomes may be affected based on the Pt Answers: Randomisation is stratified by factors that will (in our experience) impact the primary outcome (length of stay and days alive and out of hospital). Stratification factors are diversion type and recruiting centre (outlined on page 12, lines 345-346). This will encompass institutional variations in ERAS use/protocols and longer recovery from neobladder. Whilst it would be nice to stratify for neoadjuvant chemotherapy use, stage and gender, we do not believe these will affect the primary outcome. We also note that the relatively large sample size of 320 patients should ensure that the two groups are balanced with respect to key factors. We will, of course, investigate the characteristics of both trial arms and perform adjusted analyses as appropriate (as sensitivity analyses). We are not primarily measuring oncological outcomes in the iROC trial. We expect the RAZOR study to shortly report longer term oncological outcomes form open and extra-corporeal RARC.
5-Surgeon characteristics: is experience with intracorporeal diversion included?
Answer: Yes, surgeons participating in the study have all performed at least 30 iRARCs in total, and at least 10 iRARCs in the last two years per year prior to performing RCs in the trial. Answer: We thank the reviewer for this comment. Yes, surgeons participating in the study have all performed at least 30 intracorporeal RARCs in total, and at least 10 intracorporeal RARCs per year in the last two years prior to performing RCs in the trial (clarified on page 10, line 282). In practice these are minimum requirements, and we can explore the relation between individual surgeon experience and variables such as operative time and recovery outcomes. In a similar way, we will have data for prior continent diversion experience and will explore the relation between prior experience and outcomes measured in iROC.
Does the surgeon fatigue test change or is it variable in time?
As one surgeon does this over and over, answers may become rote, rendering data inaccurate.
Answer: As addressed in reviewer 1 question 2, we acknowledge that prior surgeries may impact fatigue and it will not control for this. In terms of the duration of procedure, we would expect that to impact on these measures and the tool would detect such differences. The questionnaire needs to be deployed immediately after surgery as it is intended to rate the specific dimensions associated with the procedure that has just been completed.
3.
Variant histologies may effect surgical technique/difficulty, would consider just using pure urothelial carcinoma (or UC with only minimal variant histology).
Answer: We thank the reviewer for this comment. As with reviewer 1 comments 3 & 4, we agree that this factor could impact oncological outcome, but we do not believe it will affect the primary outcome measure and recovery from RC. We also plan to measure the effect of robotic and open surgery in a "real world" context in which cases are not selected for one procedure over the other. As such, we have allowed all patients undergoing RC for cancer to be included. We do not believe it will alter the mode or difficulty of radical cystectomy and all patients will receive a lymphadenectomy.
4. How will you investigate time differences between diversion types and any ensuing effects on outcomes? (i.e. intracoporeal ONB takes longer than IC, both of which will take longer than open diversions).
Answer: Randomisation stratification factors include diversion type (outlined on page 12, lines 345-346).
How will you account for bias in fitness tracking as patients may alter their activity, knowing they are only tracked for a period of time. Could consider making this a constant (if feasible)?
Answer: The reviewer highlights the Hawthorne effect which is common to trials measuring behaviour. While it is difficult to account for this entirely, we have attempted to mitigate and minimise this effect. We opted to use a blinded (no display) wrist worn tracker to ensure that patients cannot use this for goal-setting. Additionally, any bias across both arms should be similar. We are restricted by limited device data storage of up to 30 days. After rigorous testing, we ultimately decided on 7 days as a safe duration for tracker usage, as it allows up to 2 weeks for transit through the post for data extraction. We believe that 7 days will provide a representative measure of activity over a time period (including variations for eg. weather, weekends etc. for low activity; clinic attendance, shopping days for high activity).
Recommend statistics review to evaluate need for any power calculations or additional
analyses that may prove useful for your comparisons.
Answer: We thank the reviewer for this. The last two reviewers appear to be Statisticians, and so we believe this has been performed by the BMJ Open peer review process. Regardless, our team includes a statistician, amongst other trial methodologists.
Reviewer: 3
Reviewer Name: Abolfazl Hosseini Institution and Country: Karolinska university hospital, Stockholm, Sweden
Please state any competing interests: nothing
Please leave your comments for the authors below
Very well-designed study. Some comments which should be considered:
Answer: We thank the reviewer for this comment.
Early recurrence within 2 first years after cystectomy should also be mentioned as one of oncological outcomes
Answer: We thank the reviewer for this comment. Within the oncological outcomes we have listed i).
Port site recurrence free survival, ii). Location of recurrence/metastases and iii). Overall and Cancer free survival at 12 and 18 months. (lines 191-195) . Currently, we only have funding for 18 months follow up. We are applying for further funding and aim to follow for 5 years, but to date do not have this in place.
Surgeons undertaking iRARC need to have completed more than 30 cases (RARC with totally intracorporeal urinary diversion, it should be emphasised)
Answer: Yes, surgeons participating in the study have all performed at least 30 iRARCs in total, and at least 10 iRARCs per year in the last two years prior to performing RCs in the trial. (clarified on page 10, line 282)
Please describe exclusion criteria for orthotropic neobladder as well
Answer: This study allows surgical practice as per each unit. This is necessary given the resources available, the recruitment methods and UK practice. We estimate that most patients within this study will receive Ileal Conduit. We have detailed that reconstructive choice should be in keeping with usual practice in each hospital (page 11, lines 304-305). We have added a reference that describes selection to 305 (ref 38) to point the reader to a useful resource. If the reviewer and editor feels this is necessary, we are happy to add the exclusion criteria for neobladder, but we feel that this is a distraction for the trial itself in this manuscript.
4. For more detailed description of "duration os surgery" as an intra-operative element, the operation time has be divided in cystectomy, LND and urinary diversion.
Answer: Cystectomy, LND, diversion and total (knife-to-skin to closure) times are being collected separately and cumulatively for each case. This has been clarified on page 13, lines 394- Answer: We thank the reviewer for this comment. We agree and have added to the abstract "Treatment allocation will occur after trial entry and consent." (abstract on page 2, lines 45-46). This has been clarified on page 12, lines 347.
2.
There is little about what will happen with missing data. I realise that the authors state that a detailed analysis plan will be written later, but it would be good to have some idea. In the protocol it says that participants can withdraw at any time without prejudicing their treatment.
But it is not until you get to the information sheet that you find out what will happen to those peoples' data. It is also possible that participants will be withdrawn for other reasons than their desire to leave the study. What will happen to the data, and future data collection, for these individuals.
Answer: We hope we will obtain a complete dataset for the primary outcome measure as this metric is available through HES data and hospital billing records. Patients withdrawing from the trial midway through will be counselled regarding the end of active participation (i.e. collection of secondary outcomes) but the continued collection of the primary outcome measure. New text to explain this is inserted on page 15, lines 451-456. For secondary outcomes, we will try to minimise incomplete collection through the use of research nurses. For missing values, the following sentence has been added to the analysis section mentioning that the use of multiple imputation will be considered as appropriate: 'The use of regression (to adjust for variables related to missingness) and multiple imputation methods (chained equations) will be considered as sensitivity analyses.'(page 15, lines Answer: The reviewer raises an important point here which is part of the motivation for performing an internal pilot to check the sample size assumptions. This has now been done and the reviewer's suspicion is correct. The original outcome (DAOH) is left-skewed as is the log-transformed version.
Consequently, we intend to transform the outcome using log(90-DAOH) prior to analysis. In our pilot data, this transformed variable is approximately normally distributed and the other sample size assumptions (e.g. standard deviation) are met. We have updated the sample size to reflect this. We now say (in Sample Size):
'The primary outcome measure is log(90-DAOH) within the first 90 days from surgery.'(page 9, line 249) and 'We note that the original primary outcome was log(DAOH). However, a review of blinded internal pilot data suggested that this outcome would be left skewed and that other sample size assumptions would not hold.'(page 9, lines 257-259)
The Abstract has also been updated accordingly:
The primary outcome will be transformed and analysed using regression. All statistical assumptions will be investigated. (page 2, lines 50-52)
4. In the analysis plan it will be good to discuss what will be done with the minimisation variables. It is normal to adjust for these, maybe as a secondary analysis.
Answer: The primary analysis now reflects the fact we plan to adjust for the minimisation variables using regression methods. We now say (in Statistical Analysis):
'The primary analysis will be a comparison of the transformed primary outcome DAOH using regression to adjust for the minimisation factors.'
We note that there may be two or three surgical teams per site. However, each team will perform both procedures (unlike in a cluster RCT) and therefore a fixed-effect adjustment for team (and/or site) should suffice. No sample size inflation is deemed necessary for either surgical team or site.
Reviewer: 5
Reviewer Name: Sameer Parpia Answer: Thank you for asking this question. The internal feasibility study aims to look at recruitment rates, rates of allocated treatment acceptance and to compare our'in trial'data with those from the BAUS national audit that were used to power the study. The review of the sample size calculation will be performed by the trial statistician using blinded aggregate data. We note here that the statistician will only review the distribution and standard deviation of the aggregate outcome data. The manuscript has been modified to clarify this (pages 9-10, lines 262-269 and page 2, line 53-55).
Answer: The success of the trial depends primarily on the results of the primary analysis, rather than those of the secondary analyses. Hence, we are not planning to adjust the secondary analyses for multiple testing. Answer: The internal feasibility is designed to refine trial recruitment and to allow correction of the sample size. We did not include termination conditions.
Sample size
Was the sample size quoted (160 in each group) inflated for any possible patient attrition?
Answer: We estimate attrition for the primary outcome will be low (<5%) as this data is available from hospital billing records/HES data. The possible explanations would be post-op deaths (i.e. do not reach 90 days after surgery) and those who totally withdraw from collection (i.e. not just from secondary outcome collection). We are assessing this as part of our internal feasibility analysis, and if a higher attrition rate is expected, the power calculation will be adjusted to reflect this.
Further there is also presumably a small possibility of patients diving either during or soon after surgery -would these patients be removed from he study or would they have a Primary outcome of zero days?
Answer: The primary outcome is based on the variable 'Days Alive and Out of Hospital'. Any patient who dies immediately (or indeed within their first stay in hospital) would have a value of one recorded (to allow log10 transformation) and would certainly be included in the primary analysis.
Analytical approaches
The authors acknowledge that: "Variations in surgical team performance produce wide
